Full Press Release Details
to Participate in Morgan Stanley's 19th Annual Global Healthcare Conference
LAUSANNE, Switzerland,
September 9, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those
affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and
solid tumors, announced today that Joseph Camardo, MD, Chief Medical Officer, and Jennifer Herron, Chief Commercial Officer, will participate
in a fireside chat at Morgan Stanley's 19th Annual Global Healthcare Conference on Tuesday, September 14th
of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website,
ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted
antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm
for patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed
ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell
lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab
tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial
for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple PBD-based ADCs in ongoing clinical
and preclinical development.
is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,
please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
ZYNLONTA is a registered trademark
of ADC Therapeutics SA.
Tel.: +1 914-552-4625